Clinical trial · no report yet · Phase 1/Phase 2
FAKTION
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
- NCT01992952 ↗
- Active not recruiting
- Velindre NHS Trust
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
- Phase
- Phase 1/Phase 2
- Status
- Active not recruiting
- Conditions
- Estrogen Receptor Positive Breast Cancer
- Interventions
- AZD5363; Placebo; Fulvestrant
- Arms
- AZD5363 plus fulvestrant · Experimental
- Placebo plus fulvestrant · Active comparator
- Enrollment
- 149
- Primary outcomes
- Phase 1b primary outcome measure: Maximum Tolerated Dose of AZD5363 in combination with fulvestrant
- Phase 2 primary outcome: Progression free survival (PFS)
- Sponsor
- Velindre NHS Trust with AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board
- Start
- May 7, 2014
- Primary completion
- Mar 2019
- Results posted
- No
- Registry record
- NCT01992952 · updated Nov 26, 2025
Publications
linked from the registry- Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. PubMed 35671774
- Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. PubMed 32035020